Hepatic angiosarcoma in a patient treated with Obeticholic acid for primary biliary cholangitis
Arif A. Arif1
1Department of Medicine, University of British Columbia, Vancouver, BC, Canada
2Department of Surgery, University of British Columbia, Vancouver, BC, Canada
3Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC Canada
4Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Division of Gastroenterology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada.
2Department of Surgery, University of British Columbia, Vancouver, BC, Canada
3Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC Canada
4Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Division of Gastroenterology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada.
Hepatology Forum - DOI: 10.14744/hf.2024.2024.0035
Abstract
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease which can lead to cirrhosis and development of hepatocellular carcinoma. PBC is not known to be associated with hepatic angiosarcoma. Second line treatments for PBC, including obeticholic acid, have had less than a decade of clinical use. We present a case of a patient with PBC treated with obeticholic acid who subsequently developed hepatic angiosarcoma. The patient is now on active surveillance following resection of the angiosarcoma. The development of this rare and aggressive cancer should prompt closer post-marketing surveillance for obeticholic acid.
Keywords: Hepatic angiosarcoma, primary biliary cholangitis, obeticholic acid
